A COMPENDIOUS REVIEW ON THE METABOLIC SYNDROME; ITS IMPACT ON THE QUALITY OF LIFE
DOI:
https://doi.org/10.22159/ajpcr.2018.v11s4.31687Keywords:
Cardiovascular disorders, Inflammation, Insulin resistance, Metabolic syndrome, Obesity, OccurrenceAbstract
Background: Metabolic syndrome (MetS), a comprehensive condition is universally described as a group of several causative factors or abnormalities directly linked with insulin resistance that obviously augment the threat mainly for coronary heart disease, diabetes mellitus Type 2, some types of cancers and sleep disturbances, etc. MetS is a contemporary condition that covers a wide-ranging display of disorders with definite metabolic anomalies demonstrating at different times. Consequently, the threat of MetS remains epidemic. This review will potentially study significant factors such as central adiposity, insulin resistance, hypertension, and dyslipidemia; increased inflammation, environmental factors, and genetic predisposition are involved in MetS development.
Purpose: This review provides the available facts to validate the relationship between MetS and quality of life.
Methods: A thorough exploration in many search engines such as PubMed, Medline, Science direct, EMBASE, and Google scholar was carried out to recognize qualified studies.
Results: Almost all studies suggested that MetS is significantly associated with impair quality of life. Lifestyle intervention holds the early preference and such non-pharmacological therapy combines specific suggestion on diet and physical activity with behavioral strategies. For the individuals, where contributing factors are not sufficiently condensed with lifestyle changes, pharmacological treatment should be considered.
Conclusion: Therefore, the current study reviews the outline of literature interrelated with the MetS's characterization, epidemiological existence, pathological process, and management advance for all the risk factors encompassing metabolic disorder.Downloads
References
Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - A new worldwide definition. Lancet 2005;366:1059-62.
Kaur J. Assessment and screening of the risk factors in metabolic syndrome. Med Sci 2014;2:140-52.
Grundy SM. Point: The metabolic syndrome still lives. Clin Chem 2005;51:1352-4.
Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal. Joint statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care 2005;28:2289-304.
Dabou S, Telefo PB, Sama LF. Evaluation of dietary habits and lifestyle on the prevalence of metabolic syndrome and obesity in undergraduate university students in Cameroon: A cross sectional study. J Metab Synd 2018;7:1.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009;120:1640-5.
National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults
(Adult Treatment Panel III). Circulation 2002;106:3143-421.
Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: Pathophysiology, management, and modulation by natural
compounds. Ther Adv Cardiovasc Dis 2017;11:215-25.
World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO
Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva. World Health Organization; 1999. WHO/NCD/NCS/99.2.
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European group for the study of insulin resistance
(EGIR) Diabet Med 1999;16:442-3.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and
treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
Zimmet PZ, Alberti KG, Shaw JE. Mainstreaming the metabolic syndrome: A definitive definition. Med J Aust 2005;183:175-6.
Shaw JE, Chisholm DJ. 1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Med J Aust 2003;179:379-83.
Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia 2003;1:137.
Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, et al. Prevalence of the metabolic syndrome and its relation to all-cause
and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-76.
Hu G, Lindström J, Jousilahti P, Peltonen M, Sjöberg L, Kaaja R, et al. The increasing prevalence of metabolic syndrome among Finnish men
and women over a decade. J Clin Endocrinol Metab 2008;93:832-6.
Ilanne-Parikka P, Eriksson JG, Lindström J, Hämäläinen H, Keinänen-Kiukaanniemi S, Laakso M, et al. Prevalence of the metabolic
syndrome and its components: Findings from a Finnish general population sample and the diabetes prevention study cohort. Diabetes Care
;27:2135-40.
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition
examination survey. JAMA 2002;287:356-9.
Cortez-Dias N, Martins S, Belo A, Fiuza M, Investigadores do estudo VALSIM. Comparison of definitions of metabolic syndrome in relation
to risk for coronary artery disease and stroke. Rev Port Cardiol 2011;30:139-69.
Lechleitner M. Obesity and the metabolic syndrome in the elderly – a mini-review. Gerontology 2008;54:253-9.
Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.
Desroches S, Lamarche B. The evolving definitions and increasing prevalence of the metabolic syndrome. Appl Physiol Nutr Metab
;32:23-32.
Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB, et al. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988-1994. Arch Intern Med 2003;163:427-36.
Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: Contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011;18:629-39.
Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-801.
Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002;32 Suppl 3:14-23.
Bremer AA, Mietus-Snyder M, Lustig RH. Toward a unifying hypothesis of metabolic syndrome. Pediatrics 2012;129:557-70.
Vague IJ, Alessi MC, Mavri A, Morangi PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003;1:1575-9.
de Ferranti S, Mozaffarian D. The perfect storm: Obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 2008;54:945-55.
Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 1996;19:390-3.
Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-9.
Weiss R, Caprio S. The metabolic consequences of childhood obesity. Best Pract Res Clin Endocrinol Metab 2005;19:405-19.
Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84.
Flegal KM, Carroll MD, Ogden CL Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288:1723-7.
Festa A, D’Agostino R Jr., Williams K, Karter AJ, Davis EJ, Tracy RP, et.al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes 2001;25:1407-15.
Hunter I, Soler A, Joseph G, Hutcheson B, Bradford C, Zhang FF, et al. Cardiovascular function in male and female JCR: LA-cp rats: Effect of high-fat/high-sucrose diet. Am J Physiol Heart Circ Physiol 2017;312:H742-H751.
Koster A, Stenholm S, Alley DE, Kim LJ, Simonsick EM, Kanaya AM, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring) 2010;18:2354-61.
Gill H, Mugo M, Whaley-Connell A, Stump C, Sowers JR. The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci 2005;330:290-4.
Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA; Conference Participants. Clinical management of metabolic syndrome: Report of the American heart association/national heart, lung, and blood institute/American diabetes association conference on scientific issues related to management. Circulation 2004;109:551-6.
Vanecková I, MaletÃnská L, Behuliak M, Nagelova V, Zicha J, Kunes J. Obesity-related hypertension: Possible pathophysiological mechanisms. J Endocrinol 2014;223:R63-78.
Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-97.
Gonal F, Deshmukh A, Shah S, Mehta JL. Triad of metabolic syndrome, chronic kidney disease, and coronary heart disease with a focus on microalbuminuria: Death by overeating. J Am Coll Cardiol 2011;57:2303-8.
Dai Y, Mercanti F, Dai D, Wang X, Ding Z, Pothineni NV, et al. LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells. Biochem Biophys Res Commun 2013;437:62-6.
Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J 1991;121:1274-82.
Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003;115 Suppl 8A:24S-28S.
Pant S, Deshmukh A, Gurumurthy GS, Pothineni NV, Watts TE, Romeo F, et al. Inflammation and atherosclerosis – Revisited. J Cardiovasc Pharm Ther 2014;19:170-8.
Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signalling from the insulin receptor. Proc Natl Acad Sci USA 1994;91:4854-8.
Tsigos C, Kyrou I, Chala E, Tsapogas, Stavridis JC, Raptis SA, et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999;48:1332-5.
Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-50.
Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-42.
Wisse BE. The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-800.
Lewisand GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans: implications for the insulin resistant state. Diabetes Care 1996;19:390-3.
Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005;36:232-40.
Ordovas JM. Genetic links between diabetes mellitus and coronary atherosclerosis. Curr Atheroscler Rep 2007;9:204-10.
Poulsen P, Levin K, Petersen I, Christensen K, Nielsen HB, Vaag A. Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes 2005;54:275-83.
Hansson GK. Mechanisms of disease: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
Kraemer-Aguiar LG, Laflor CM, Bouskela E. Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome. Metabolism 2008;57:1740-6.
Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol 2005;67:259-84.
Andrew R, Gale CR, Walker BR, Seckl JR, Martyn CN. Glucocorticoid metabolism and the metabolic syndrome: Associations in an elderly cohort. Exp Clin Endocrinol Diabetes 2002;110:284-90.
Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009;5:374-81.
Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997;337:869-73.
Barquero SC, Leon AM, Sadurni M, Estruch R, Casas R. Dietary strategies for metabolic syndrome: A review. J Obes Ther 2017;1:2.
Harding J, Sooriyakumaran M, Anstey KJ, Adams R, Balkau B, Briffa T, et al. The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components? Diabetes Metab 2015;41:463-9.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32.
Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-72.
Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet 2005;366:1640-9.
Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The asteroid trial. JAMA 2006;295:1556-65.
Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
Pyörälä M, Miettinen H, Halonen P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: The 22-year follow-up results of the helsinki policemen study. Arterioscler Thromb Vasc Biol 2000;20:538-44.
Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympatho adrenal system. N Engl J Med 1996;334:374-81.
Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-7.
Clark JM. The epidemiology of non-alcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40:S5-10.
Kotronen A, Yki-Järvinen H. Fatty liver: A novel component of the metabolic syndrome. Arterioscler Thromb Vascu Biol 2008;28:27-38.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
Bjørge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, Manjer J, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010;19:1737-45.
Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol 2006;169:1505-22.
Chang YC, Huang CY, Hwang LC, Chang CC. The association between helicobacter pylori infection and metabolic syndrome in a Taiwanese adult population. J Metab Synd 2017;6:4.
Hamilton GS, Solin P, Naughton MT. Obstructive sleep apnoea and cardiovascular disease. Intern Med J 2004;34:420-6.
Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005;9:211-24.
Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabol Clin Exp 2003;52:908-15.
Legro RS. A 27-year-old woman with a diagnosis of polycystic ovary syndrome. JAMA 2007;297:509-19.
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2005;90:1929-35.
Watanabe H, Obata H, Watanabe T, Sasaki S, Nagai K, Aizawa Y, et al. Metabolic syndrome and risk of development of chronic kidney disease: The niigata preventive medicine study. Diabetes Metab Res Rev 2010;26:26-32.
Akman T, Binbay M, Erbin A, Tepeler A, Sari E, Kucuktopcu O, et al. The impact of metabolic syndrome on long-term outcomes of percutaneous nephrolithotomy (PCNL). BJU Int 2012;110:E1079-83.
Babić D, Maslov B, Martinac M, Nikolić K, Uzun S, Kozumplik O. Bipolar disorder and metabolic syndrome: Comorbidity or side effects of treatment of bipolar disorder. Psychiatr Danub 2010;22:75-8.
Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci 2012;69:741-62.
Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol 2012;39:212-8.
Wong ND. Intensified screening and treatment of the metabolic syndrome for cardio vascular risk reduction. Prev Cardiol 2005;8:47-54.
Deen D. Metabolic syndrome: Time for action. Am Fam Physician 2004;69:2875-82.
Youngwanichsetha S. Healthy eating for prevention of the metabolic syndrome. J Nutr Food Sci 2018;8:3.
Diego J, Camacho H, Hernández-Camachob M. Clinical update on metabolic syndrome. Rev Esp Nutr Hum Diet 2017;21:384-92.
Jarbøl DE, Larsen PV, Gyrd-Hansen D, Søndergaard J, Brandt C, Leppin A, et al. Determinants of preferences for lifestyle changes versus medication and beliefs in ability to maintain lifestyle changes. A population-based survey. Prev Med Rep 2017;6:66-73.
Hoffmann IS, Cubeddu LX. Increased blood pressure reactivity to dietary salt in patients with the metabolic syndrome. J Hum Hypertens 2007;21:438-44.
Anderssen SA, Carroll S, Urdal P, Holme I. Combined diet and exercise intervention reverses the metabolic syndrome in middle-aged males: Results from the oslo diet and exercise study. Scand J Med Sci Sports 2007;17:687-95.
Esposito K, Giugliano D. Mediterranean diet and the metabolic syndrome: The end of the beginning. Metab Syndr Relat Disord 2010;8:197-200.
Blair SN, Cheng Y, Holder JS. Is physical activity or physical fitness more important in defining health benefits? Med Sci Sports Exerc 2001;33:S379-99.
Magkos F, Yannakoulia M, Chan JL, Mantzoros CS. Management of the metabolic syndrome and Type 2 diabetes through lifestyle modification. Annu Rev Nutr 2009;29:223-56.
Papakonstantinou E, Lambadiari V, Dimitriadis G, Zampelas A. Metabolic syndrome and cardiometabolic risk factors. Curr Vasc Pharmacol 2013;11:858-79.
Lakka TA, Laaksonen DE, Lakka HM, Männikkö N, Niskanen LK, Rauramaa R, et al. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med Sci Sports Exerc 2003;35:1279-86.
Roberts CK., Won D., Pruthi S., Lin SS., Barnard, R. J. Effect of a diet and exercise intervention on oxidative stress, inflammation and monocyte adhesion in diabetic men. Diabetes Research and Clin Pract 2008;73:249-59.
Laaksonen DE, Lakka HM, Salonen JT, Niskanen LK, Raurama R, Lakka TA. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care 2002;25:1612-1618.
Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93.
Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014;2014:943162.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
